The Japan Veterinary Vaccines Market was valued at $65.12 Million in 2024 and projected to reach to $91.13 Million by 2029, representing a compound annual growth rate of 7.0%. Japan's veterinary vaccines market is positioned for sustained expansion, driven by increasing pet ownership, heightened disease awareness, and stringent regulatory requirements for animal health.
Japan's veterinary vaccines market is valued at USD 65.12 million in 2024, with a projected CAGR of 7.0% through 2029, reaching USD 91.13 million. This growth outpaces the global average of 6.1%, indicating Japan's accelerating investment in animal health.
Rising pet ownership in Japan, particularly among urban populations, is driving demand for companion animal vaccines. The trend reflects changing lifestyle preferences and increased willingness to invest in preventive pet healthcare.
Japan's sophisticated veterinary healthcare system, supported by stringent regulatory standards and high-quality animal health facilities, creates a premium market environment for innovative vaccine products and services.
Japan's livestock sector maintains strict biosecurity protocols and disease prevention measures, driving consistent demand for cattle, swine, and poultry vaccines to ensure food safety and agricultural productivity.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | CHINA (Disease) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 6.1% from 2024 to 2029 |
| Largest Segment | VETERINARY HOSPITALS (End User) |
| Market Size Base Year | 9.91 (2024) |
| Revenue Forecast | 13.33 (2029) |
| Segments Covered | Type, Disease, Technology, Route Of Administration, End User |
5 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| KBNP,INC. | South Korea | Private Company | Poultry and swine medicines,Cattle and aquaculture products,Companion animal medicines, |
| KOMIPHARM INTERNATIONAL | South Korea | Public Company | Veterinary vaccines,Veterinary pharmaceuticals (injectable, oral, topical),Disinfectants and bio-fertilizers, |
| BAYER AG | Germany | Public Company | Crop Science,Pharmaceuticals,Consumer Health, |
| HESKA CORPORATION | United States | Private Company | In-clinic analyzers (chemistry, hematology, blood gas, coagulation, immunodiagnostics),Imaging and informatics (digital radiography, mobile DR, ultrasound, Cloudbank, telecytology),Point-of-care infectious disease tests and allergy products/services, |
| QUIMTIA S.A. | Brazil | Private Company | Poultry feed and premix,Swine feed and premix,Bovine and ruminant nutrition, |
| TEREOS | France | Private Company | Sugar and sweetening ingredients (including organic cane and beet sugar),Starches and derivatives (food, industrial, bioplastics, corrugated cardboard),Alcohol and ethanol (food, industrial, fuel, and pharma uses), |
| SANOFI | France | Public Company | Pediatric and combination vaccines (polio, pertussis, Hib, hexavalent),Other vaccines (RSV, hepatitis A, typhoid, yellow fever, rabies),Immunology and inflammation therapies, |
| PATTERSON COMPANIES, INC | United States | Private Company | Dental consumables and equipment,Dental software and practice optimization,Animal health products and private label, |
| MERCK & CO., INC. | United States | Public Company | Oncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations),Vaccines (Gardasil, pediatric, pneumococcal, rotavirus),Cardiometabolic, infectious disease, and other human pharma, |
| ZOETIS | United States | Public Company | Parasiticides,Vaccines,Dermatology, |
| ELANCO | United States | Public Company | Companion animal parasiticides (Seresto, K-9 Advantage, Advantix, Advocate, Credelio, Interceptor Plus, Drontal),Companion animal vaccines and therapeutics (Galliprant, Atopica, Onsior, Tru Family, cardiovascular and dermatology),Farm animal feed additives and antibiotics (Rumensin, Experior, Baytril, Denagard, Pulmotil, Surmax, Hemicell), |
| CEVA | United States | Public Company | 5G/5G-Advanced baseband DSP and RAN IP (PentaG-RAN, Ceva XC20/XC21/XC23, PentaG2, Ceva-BX2),Connectivity IP (Ceva-Waves Bluetooth, Wi-Fi, UWB, Links, DragonFly NB-IoT),Sensing, audio, and sensor-fusion IP (Ceva-SensPro, Ceva-BX1, ClearVox, RealSpace, MotionEngine), |
| VIRBAC | France | Public Company | Companion animal parasiticides (e.g., Prevexto),Companion animal specialty therapeutics (dermatology, stress, mobility, kidney, dental),Companion animal vaccines and antibiotics, |
| PHIBRO ANIMAL HEALTH CORPORATION | United States | Public Company | Animal Health (antibacterials, anticoccidials, nutritional specialties, vaccines, adjuvants, microbial and bioproducts),Mineral Nutrition (trace mineral formulations and concentrations),Performance Products (specialty ingredients for personal care, industrial chemicals, catalysts), |
| HESTER BIOSCIENCES LIMITED | India | Public Company | Poultry vaccines,Large-animal vaccines (cattle, small ruminants),Companion animal and specialty biologics, |
| NEOGEN CORPORATION | United States | Public Company | Food Safety diagnostics, media, and sanitation,Animal Safety reagents, instruments, and animal care products,Genomics services for livestock and companion animals, |
| TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD. | China | Public Company | Veterinary vaccines,Chemical drugs and APIs,Feed and functional additives, |
| CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD. | China | Public Company | Animal Disease Epidemic Prevention (vaccines and biologicals),Animal Disease Treatment (veterinary chemical products),Animal Nutrition (feed, premixes, additives, raw material trade), |
| JINYU BIO-TECHNOLOGY CO., LTD. | China | Public Company | Porcine vaccines (PRRS, pseudorabies, FMD, circovirus, swine fever, influenza, TGE),Poultry vaccines (avian influenza, Newcastle disease, IBD, IB, egg drop syndrome),Ruminant and brucellosis vaccines, |
KBNP,INC. is a private company based in South Korea with 96 employees, founded in 1988.
KOMIPHARM INTERNATIONAL is a public company based in South Korea with 161 employees, established in 1972.
Bayer AG is a public company based in Germany with 87,757 employees, founded in 1863.
HESKA CORPORATION is a private company based in the United States with 808 employees, founded in 1988.
QUIMTIA S.A. is a private company based in Brazil, established in 1975.
TEREOS is a private company based in France with 10,241 employees, founded in 1996.
Sanofi is a public company based in France with 74,846 employees, established in 1994.
PATTERSON COMPANIES, INC is a private company based in the United States with 7,600 employees, founded in 1877.
Merck & Co., Inc. is a public company based in the United States with 74,000 employees, established in 1891.
Zoetis is a public company based in the United States with 14,500 employees, founded in 2012.
Elanco is a public company based in the United States with 9,650 employees, founded in 1954.
Ceva is a public company based in the United States with 400 employees, established in 1999.
Virbac is a public company based in France with 6,442 employees, founded in 1968.
Phibro Animal Health Corporation is a public company based in the United States with 2,475 employees, established in 1946.
HESTER BIOSCIENCES LIMITED is a public company based in India, founded in 1987.
Neogen Corporation is a public company based in the United States with 2,974 employees, established in 1981.
TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD. is a public company based in China with 2,803 employees, founded in 1998.
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD. is a public company based in China with 3,996 employees, established in 1998.
JINYU BIO-TECHNOLOGY CO., LTD. is a public company based in China with 1,881 employees, founded in 1992.
Japan's veterinary vaccines market was valued at USD 65.12 million in 2024 and is expected to grow to USD 91.13 million by 2029.
Japan's veterinary vaccines market is projected to grow at a compound annual growth rate (CAGR) of 7.0% between 2024 and 2029.
Key drivers include rising pet ownership, stringent biosecurity regulations, high awareness of zoonotic diseases, and increasing preventive healthcare spending in Japan.
Japan's 7.0% CAGR exceeds the global veterinary vaccines market CAGR of 6.1%, positioning Japan as a faster-growing market within the Asia Pacific region.
Japan's market includes companion animal vaccines (dogs, cats) and livestock vaccines, with companion animal vaccines representing a significant share due to high pet ownership rates.
This study involved the extensive use of both primary and secondary sources. The research process involved examining various factors affecting the industry to identify segmentation types, industry trends, key players, the competitive landscape, fundamental market dynamics, and key players' strategies.
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, SEC filings of companies and publications from government sources such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), American Veterinary Medical Association (AVMA), Animal Health Institute (AHI), National Animal Health Laboratory Network (NAHLN), and Food and Agriculture Organization of the United Nations (FAO) were referred to identify and collect information for the global veterinary vaccines market study. It was also used to obtain important information about key players, market classification & segmentation according to industry trends, down to the bottom-most level, and key developments from market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and other key executives from various companies and organizations in the veterinary vaccines market. The primary sources from the demand side include hospitals & clinics, physiotherapy clinics, and home care settings. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.
A breakdown of the primary respondents is provided below:
*C-level primaries include CEOs, CFOs, COOs, and VPs.
*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note: Companies are classified into tiers based on their total revenue. As of 2025, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.
Source: MarketsandMarkets Analysis
To know about the assumptions considered for the study, download the pdf brochure
For the global market value, annual revenues were calculated using revenue mappings of major product manufacturers and OEMs active in the global veterinary vaccines market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/sub-segments was done for the major players (who contribute at least 70-75% of the market share at the global level). Also, the global veterinary vaccines market was split into various segments and sub-segments based on:
The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

After determining the overall size of the global veterinary vaccines market using the above-mentioned methodology, the market was split into several segments and subsegments. The data triangulation and market breakdown procedures were employed, where applicable, to complete the overall market engineering process and derive the exact market value data for the key segments and subsegments. The extrapolated market data was triangulated by studying various macro indicators and regional trends from both demand- and supply-side participants.
A veterinary vaccine is a biological preparation that provides immunity by stimulating an animal’s immune system to recognize and combat a specific pathogen. The veterinary vaccines market includes live attenuated, inactivated, recombinant, and toxoid vaccines for a wide range of animals, including poultry, livestock, porcine, aquaculture, and companion animals. Vaccination improves animal health, reduces the incidence of zoonotic diseases, supports higher productivity, and helps secure economic stability.
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
GEOGRAPHIC ANALYSIS
COMPETITIVE LANDSCAPE ASSESSMENT
Full forecast, segment splits, and company analysis for all Veterinary Vaccines Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report